Intec Parent, Inc. develops pharmaceutical products. The company is headquartered in Jerusalem, Israel.
Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2000
Active, not recruiting
1
100.0%
No approval data available
- Indaptus Therapeutics discontinued enrollment in its Decoy20 combination study and now has no active clinical development programs, pausing further development of its lead immunotherapy candidate. - The company completed a $12.0 million private placement in June 2026, issuing 20 million shares at $0.60 per share, strengthening its liquidity position to approximately $11.6 million in cash and investments. - Research and development expenses fell 83% to $0.4 million in Q2 2026, while net loss narrowed to $1.8 million from $5.2 million a year earlier. - Indaptus began a research collaboration in neurological disorders and sleep as an extension of its immunotherapy research while evaluating strategic alternatives, including potential acquisitions or business combinations.
- Indaptus Therapeutics announced that Decoy20 monotherapy induced a partial response in a urothelial cancer patient with liver metastases who had previously received anti-PD-1 therapy. - The company has initiated combination therapy testing with seven patients receiving Decoy20 plus tislelizumab, with early results showing one patient with stable disease and two with disease progression. - Indaptus raised approximately $5.7 million in gross proceeds through convertible promissory notes to strengthen its balance sheet and support ongoing clinical development. - The company plans to report additional combination trial data later this year as it continues to evaluate its novel Decoy platform technology.
- Indaptus Therapeutics receives Clinical Trial Authorization from Health Canada to expand its ongoing U.S. clinical trial INDP-D101 for its lead cancer immunotherapy candidate Decoy20. - The company plans to submit an amendment for a combination trial pairing Decoy20 with Beigene's PD-1 checkpoint inhibitor tislelizumab, broadening the therapeutic approach. - Decoy20's unique mechanism activates both innate and adaptive immune responses through multiple pathways, showing promise in pre-clinical studies against various solid tumors.
- Incyte anticipates a transformational 2025 with multiple potential drug launches and pivotal trial readouts across its oncology and inflammation & autoimmunity portfolio. - Indaptus Therapeutics plans to launch a combination cohort trial of Decoy20 with BeiGene's tislelizumab and expand clinical trial sites in the first half of 2025. - Indaptus' Decoy20 demonstrated a broad immune response across multiple tumor types, showing potential as a monotherapy and in combination with checkpoint inhibitors.
- Indaptus Therapeutics reported a 26% decrease in operating expenses for Q3 2024, driven by the completion of certain manufacturing processes for Decoy20. - The Phase 1 clinical trial for Decoy20 has progressed, with six patients completing one month of treatment at the 3 x 10^7 dose, and unrestricted enrollment authorized. - A clinical supply agreement with BeiGene Switzerland GmbH will advance the evaluation of Decoy20 in combination with tislelizumab, set to begin in 2025. - Indaptus is seeking additional capital to fund operations beyond Q1 2025, while facing financial and operational risks that could impact its long-term stability.
- Indaptus Therapeutics and BeiGene have entered a clinical supply agreement to evaluate the combination of Decoy20 and tislelizumab in cancer treatment. - The planned clinical trial will assess the synergistic effects of Decoy20, an immune stimulator, with tislelizumab, BeiGene's anti-PD-1 antibody. - Preclinical studies have shown that Decoy20, combined with a PD-1 inhibitor, induced complete cancer regressions and immunological memory in animal models. - The clinical trial, anticipated to begin in 2025, aims to improve outcomes for challenging cancers like liver, colon, and pancreatic cancer.
